Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:10:57 EDT Sat 27 Apr 2024
Enter Symbol
or Name
USA
CA



Q:HCM - HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS - http://www.hanovercapitalholdings.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
HCM - Q8.918.25·18.695.018.16-0.83-4.4185.43,1852,41418.99  18.99  17.4620.73  10.6819:43:0208:3015 min RT 2¢

Recent Trades - Last 10 of 2414
Time ETExPriceChangeVolume
19:43:02Q18.24-0.751
18:52:15Q18.16-0.8310
16:00:02Q18.16-0.83123
16:00:02Q18.16-0.8353
16:00:02Q18.16-0.831,300
16:00:02Q18.16-0.83539
16:00:02Q18.16-0.8310,500
16:00:02Q18.16-0.83100
16:00:02Q18.16-0.83100
16:00:02Q18.16-0.839

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-26 08:30U:HCMNews ReleaseHUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
2024-04-05 04:30U:HCMNews ReleaseHUTCHMED Highlights Data to be Presented at AACR Congress 2024
2024-04-02 00:30U:HCMNews ReleaseHUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
2024-03-27 20:00U:HCMNews ReleaseHUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
2024-03-21 20:00U:HCMNews ReleaseHUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
2024-02-28 06:30U:HCMNews ReleaseHUTCHMED Reports 2023 Full Year Results and Provides Business Updates
2024-02-06 19:00U:HCMNews ReleaseHUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
2024-02-02 03:30U:HCMNews ReleaseHUTCHMED Announces that Inmagene Exercises Option to License Two ‚  Drug ‚  Candidates as Part of Strategic Partnership
2024-02-01 03:30U:HCMNews ReleaseHUTCHMED to Announce 2023 Final Results
2024-01-29 23:54U:HCMNews ReleaseHUTCHMED Receives ELUNATE ‚ ® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
2024-01-10 19:00U:HCMNews ReleaseHUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
2023-12-12 23:30U:HCMNews ReleaseHUTCHMED Announces Continued Inclusion of ELUNATE ‚ ® (fruquintinib) and SULANDA ‚ ® (surufatinib) in the National Reimbursement Drug List in China at Current ‚  Terms
2023-12-12 19:00U:HCMNews ReleaseHUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
2023-11-30 19:00U:HCMNews ReleaseHUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO ‚  Asia and ESMO Immuno-Oncology Congresses
2023-11-08 19:11U:HCMNews ReleaseHUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA ¢ „ ¢ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
2023-10-16 04:30U:HCMNews ReleaseHUTCHMED Highlights Clinical Data to be Presented at ESMO ‚  Congress ‚  2023
2023-09-29 04:30U:HCMNews ReleaseHUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic ‚  Colorectal ‚  Cancer in Japan
2023-09-12 04:30U:HCMNews ReleaseHUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer
2023-09-11 20:00U:HCMNews ReleaseHUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in ‚  China
2023-08-28 20:00U:HCMNews ReleaseHUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer